Franklin Lakes-based BD (Becton, Dickinson and Co.) on Monday said that, effective Aug. 20, Michael Feld will serve as executive vice president and president of the Life Sciences Segment for BD. Feld succeeds Dave Hickey, who retired from BD last month after 10 years with the company.
Coming to BD from Veralto, Feld most recently served at the Danaher spinoff as president of its analytical instrument business, Hach. Prior to that, he held several senior roles at Danaher, including senior vice president and general manager of Cepheid Europe, and served as president of several other Danaher businesses, including Mammotome, XOS and Dover Motion, all focused on strategic planning, superior quality, associate development and cultural progression.
“Mike’s expertise in applying commercial and operational excellence principles to deliver impactful results, coupled with his experience in diagnostic solutions, position him well to lead our Life Sciences Segment,” Tom Polen, chairman, CEO and president of BD, said. “As we build momentum behind our BD Excellence operating system, Mike’s continuous improvement mindset will be an asset to BD as our Life Sciences team continues to drive efficiencies and meaningfully expand value for our customers, their patients and the global healthcare ecosystem.”
As president of the BD Life Sciences Segment, which includes Biosciences, Diagnostics Solutions and Specimen Management, Feld will be responsible for an organization that is delivering innovative advancements from discovery to diagnosis. Under his leadership, BD Life Sciences will continue to focus on developing solutions around smart, connected, end-to-end workflows, specimen collection and diagnostics at new care settings, which will improve the diagnosis and treatment of chronic conditions.
